ArticleMolecular neurobiology2025
Neuroprotective Effects of Rhamnosyl Icariside II in 6-OHDA-Treated PC12 Cells and Zebrafish.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bidirectional Causal Associations Between Plasma Metabolites and Parkinson's Disease.Molecular neurobiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
This study evaluated the neuroprotective efficacy and molecular mechanisms of Rhamnosyl Icariside II (RIC), a rare secondary flavonoid glycoside from Epimedium Linn plants, in 6-hydroxydopamine-induced PC12 cell and zebrafish PD models. RIC demonstrated effective prophylactic protection and reparative effects, significantly improving PC12 cell viability in both the pretreatment and postinjury models. RIC alleviated oxidative stress by reducing lactate dehydrogenase (LDH) activity and reactive oxygen species (ROS) levels, while simultaneously increasing the activities of superoxide dismutase (SOD) and glutathione (GSH). RT-qPCR and Western blot analyses revealed that RIC inhibited the intrinsic mitochondrial apoptotic pathway by upregulating the antiapoptotic protein Bcl-2, suppressing the activation of pro-apoptotic Bax, cleaved caspase-3 and caspase-9, and inhibiting the release of cytochrome c from mitochondria. RIC effectively restored motor coordination impaired by 6-OHDA in the zebrafish PD model. Collectively, RIC exhibits significant neuroprotective potential through synergistic regulation of oxidative stress and modulation of the intrinsic mitochondrial apoptotic pathway. Therefore, this study suggests that RIC could be a promising option for the treatment or prevention of neurodegenerative disorders, particularly PD.
Indexed as
Identifiers
41212294What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.